Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   INSM - Insmed - 2009 draadje

BioPharma« Terug naar discussie overzicht

INSM - Insmed - 2009 draadje

Volgen
3.044 Posts
Pagina: «« 1 ... 47 48 49 50 51 ... 153 »» | Laatste | Omlaag ↓
  2. [verwijderd] 23 oktober 2009 20:23
    quote:

    junkbond schreef:

    [quote=gismo74]
    [quote=junkbond]
    Voor het eerst sinds tijden mogen er weer vragen gesteld worden tijdens de CC. investor.insmed.com/releasedetail.cfm...
    [/quote]

    Waar maak jij uit op dat er vragen gesteld mogen worden?

    [/quote]To participate in the live conference call.. Ik dacht participatie/participeren is actief meedoen. Ik kan het mis hebben hoor
    Volgens mij bedoelen ze beluisteren van de CC.

    Verder valt het mij ook op dat ze geen business update aankondigen...
  3. gustaaf1e 23 oktober 2009 21:15
    quote:

    gismo74 schreef:

    [quote=junkbond]
    [quote=gismo74]
    [quote=junkbond]
    Voor het eerst sinds tijden mogen er weer vragen gesteld worden tijdens de CC. investor.insmed.com/releasedetail.cfm...
    [/quote]

    Waar maak jij uit op dat er vragen gesteld mogen worden?

    [/quote]To participate in the live conference call.. Ik dacht participatie/participeren is actief meedoen. Ik kan het mis hebben hoor
    [/quote]

    Volgens mij bedoelen ze beluisteren van de CC.

    Verder valt het mij ook op dat ze geen business update aankondigen...
    't zou wel tijd worden. Zitten daar hun zakken te vullen. Die 113 miljoen op te maken (hun riante salaris wordt doorbetaald). "as quickly as reasonable possible" (pb d.d. 13 augustus j.l.)ja ja.
    G
  6. [verwijderd] 28 oktober 2009 21:51
    quote:

    junkbond schreef:

    Christus! weer dik 5% eraf vandaag.. ik begin er eerlijk gezegd ook schijtziek van te worden
    met breken .77.78 komt .66-.69 als volgende steun in beeld

    hopen dat ze niets doms met geld doen,
    maar in huidige markt is geld gewoon schaars , dus indien geen overname dan moeten ze er goede deal kunnen maken

    rop update due
    ALS USA patienten nov 30, alhoewel mini aantal patienten
  9. [verwijderd] 30 oktober 2009 10:10
    quote:

    junkbond schreef:

    [quote=ludwig mack]
    [quote=junkbond]
    Christus! weer dik 5% eraf vandaag.. ik begin er eerlijk gezegd ook schijtziek van te worden
    [/quote]

    kijk dan niet, en wacht een p.b. of zo af in je mailbox ......, als je dat meer rust geeft;-)
    [/quote]Ik ben toch geen struisvogel :)
    Tja, ha ha, niets fijner dan al vast werken aan je prepensioen en er niets voor hoeven doen. De cashburn zonder navenante verdiensten doet de waarde van het aandeel per maand smelten..Meltdown,......
  18. [verwijderd] 6 november 2009 13:12
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009

    RICHMOND, Va., Nov 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2009.

    Revenues for the third quarter ended September 30, 2009 were $2.5 million, as compared to $4.1 million for the corresponding period in 2008. The decrease was primarily attributable to $1.0 million of grant revenue related to the IPLEX(TM) myotonic muscular dystrophy ("MMD") clinical trial recorded in the third quarter of 2008 and a reduction of $0.5 million in cost recovery from our IPLEX(TM) Expanded Access Program ("EAP") for Amyotrophic Lateral Sclerosis ("ALS") in Europe. The reduction in cost recovery from the EAP is largely due to the determination made by Insmed in the third quarter that its limited IPLEX(TM) inventory on hand should be conserved for the treatment of existing ALS patients.

    The net loss for the third quarter of 2009 was $150,000; break even on a dollar per share basis, compared with a net loss of $2.2 million, or $0.02 per share, in the third quarter of 2008. This $2.0 million decrease was primarily attributable to a $2.7 million decrease in total expenses, a $0.6 million improvement in investment income and a $0.2 million reduction in interest expense, which was partially offset by the $1.6 million reduction in total revenues.

    The $2.7 million decrease in total expenses was due primarily to a $3.8 million decrease in research and development expenses ("R&D Expenses"), which was partially offset by a $1.1 million increase in selling, general and administrative expenses ("SG&A Expenses").

    The lower R&D expenses reflected the elimination of manufacturing expenses following the sale of our follow-on biologics ("FOB") assets in March 2009, while the higher SG&A expenses were principally due to external finance, legal and consulting advisory services associated with the ongoing strategic review. The improvement in investment returns resulted from the increased amount of cash available for investment, and the lower interest expense was due to the reduction of the debt discount amortization associated with our 2005 convertible notes.

    For the nine months ended September 30, 2009, revenues totaled $7.9 million as compared to $8.8 million in the first nine months of 2008. Consistent with third quarter results, the decrease was primarily attributable to a year-over-year decrease of $0.5 million in grant revenue related to the IPLEX(TM) MMD clinical trial, and a reduction of $0.5 million in cost recovery during the most recent period from our IPLEX(TM) EAP in Europe.

    Net income for the nine months ended September 30, 2009 was $116.0 million, or $0.92 per share, compared to a net loss of $11.7 million, or $0.10 per share, for first nine months of 2008. This $127.7 million improvement was primarily due to the $127.8 million before tax gain on sale of our FOB assets to Merck, combined with a $2.6 million decrease in total expenses, a $0.4 million improvement in investment returns, a $0.3 million reduction in interest expense and the absence of a $0.5 million loss on investments, which was offset by $2.8 million of income tax expense on the gain on sale and a $1.0 million reduction in net revenue.

    The $2.6 million decrease in total expenses was due to a $7.3 million reduction in R&D expenses, which was partially offset by a $4.7 million increase in SG&A expenses.

    The $7.3 million reduction in R&D expenses was due primarily to a decrease in manufacturing expenses following the sale of our FOB assets in March 2009. The $4.7 million increase in SG&A expenses was due largely to a combination of the recognition of stock compensation expense for the restricted stock and restricted stock units that vested on March 31, 2009, and the award of bonuses, together with the increased finance, legal and consulting fees related to the ongoing strategic review; as previously mentioned. The $0.5 million reduction in investment loss was due to the write off of the NAPO investment, which occurred in 2008.

    "We are continuing our strategic review of alternatives with the assistance of our financial advisors, RBC Capital Markets, and have reviewed a number of high-quality opportunities," said Dr. Melvin Sharoky, Insmed's Chairman. "We remain focused on leveraging our strong balance sheet to grow our business and enhance shareholder value."

    As of September 30, 2009, Insmed had total cash, cash equivalents, short-term investments, and certificate of deposits on hand totaling $124.1 million, consisting of $122.0 million in cash and short term investments and $2.1 million in a certificate of deposit, as compared to $2.4 million of cash on hand as of December 31, 2008. The $121.7 million increase in total cash was due to the $127.8 million in before tax proceeds from the sale of Insmed's FOB assets to Merck, $4.1 million from the conversion of warrants and options into common stock, the release of a $2.1 million previously restricted certificate of deposit and $0.5 million from securities, which was partially offset by $11.8 million utilized to fund operations and $1.0 million for the partial repayment of the Company's 2005 convertible notes.

    Conference Call

    To participate in today's 8:30 AM ET conference call, please dial 800-573-4754 (U.S. callers) or 617-224-4325 (international), and provide passcode 14720373. A live webcast of the call will also be available at:

    phx.corporate-ir.net/playerlink.zhtml...

    Please allow extra time prior to the webcast to register, download and install any necessary audio software.

    The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET today at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 92577797.

    vr gr willem.
3.044 Posts
Pagina: «« 1 ... 47 48 49 50 51 ... 153 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Pharming 0,876 +0,04 +5,23%
Accsys 0,594 +0,02 +3,13%
UMG 24,240 +0,70 +2,97%
HEIJMANS KON 31,050 +0,70 +2,31%
IMCD 149,550 +3,10 +2,12%
INPOST 16,720 +0,27 +1,64%
SIGNIFY NV 21,780 +0,34 +1,59%
FASTNED 23,050 +0,35 +1,54%
ASMI 528,400 +6,80 +1,30%
Aperam 28,820 +0,36 +1,26%
BESI 126,700 +1,50 +1,20%
ASML 678,300 +8,00 +1,19%
Corbion 22,780 +0,22 +0,98%
RELX 45,180 +0,40 +0,89%
Wolters Kluwer 163,050 +1,30 +0,80%
PROSUS 40,770 +0,27 +0,65%
Galapagos 25,520 +0,16 +0,63%
UNILEVER PLC 56,120 +0,32 +0,57%
ADYEN NV 1.503,200 +8,20 +0,55%
NN Group 42,950 +0,18 +0,42%
Nedap N.V. 54,000 +0,20 +0,37%
ABN AMRO BANK N.V. 15,065 +0,05 +0,37%
AEX 896,14 +2,72 +0,30%
CTP 15,240 +0,04 +0,26%
Fagron 18,420 +0,04 +0,22%
Kendrion 10,780 +0,02 +0,19%
ArcelorMittal 24,590 +0,01 +0,04%
ASCX 1.251,41 +0,36 +0,03%
ACOMO 17,500 0,00 0,00%
DSM FIRMENICH AG 105,050 0,00 0,00%
Fugro 16,910 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 1,250 -0,33 -21,09%
AZERION 1,050 -0,05 -4,55%
Sif Holding 11,640 -0,38 -3,16%
AALBERTS NV 35,920 -0,98 -2,66%
JUST EAT TAKEAWAY 15,765 -0,38 -2,35%
Alfen N.V. 12,490 -0,27 -2,12%
WDP 19,760 -0,42 -2,08%
B&S Group SA 4,320 -0,08 -1,82%
Eurocommercial Properties 22,500 -0,35 -1,53%
CM.COM 5,800 -0,09 -1,53%
Vopak 42,440 -0,64 -1,49%
Avantium 1,800 -0,03 -1,42%
Wereldhave 13,700 -0,18 -1,30%
THEON INTERNAT 11,040 -0,14 -1,25%
SBM Offshore 16,640 -0,21 -1,25%
Basic-Fit 22,540 -0,28 -1,23%
NX FILTRATION 4,155 -0,04 -1,07%
Philips Koninklijke 24,780 -0,25 -1,00%
TomTom 5,515 -0,06 -0,99%
RANDSTAD NV 42,650 -0,39 -0,91%
Vastned 21,900 -0,20 -0,90%
SHELL PLC 30,530 -0,26 -0,84%
Heineken 69,420 -0,58 -0,83%
NSI 19,640 -0,16 -0,81%
AMG Critical Materials N.V. 14,780 -0,12 -0,81%
OCI 11,140 -0,08 -0,76%
BAM 4,096 -0,03 -0,73%
ING 15,058 -0,10 -0,69%
KPN 3,568 -0,02 -0,61%
Air France-KLM 7,664 -0,05 -0,60%
ForFarmers 3,380 -0,02 -0,59%
AMX 868,14 -5,00 -0,57%
Arcadis 61,850 -0,35 -0,56%
Sligro 10,720 -0,06 -0,56%
ALLFUNDS GROUP 5,505 -0,03 -0,54%
Ahold Delhaize 32,080 -0,17 -0,53%
Brunel 8,930 -0,04 -0,45%
PostNL 1,054 0,00 -0,38%
Akzo Nobel 60,300 -0,20 -0,33%
JDE PEET'S 18,840 -0,06 -0,32%
EXOR NV 94,300 -0,30 -0,32%
ASR Nederland 45,430 -0,12 -0,26%
Van Lanschot Kempen NV 43,800 -0,10 -0,23%
TKH 30,960 -0,04 -0,13%
RENEWI 9,700 -0,01 -0,10%
Flow Traders 21,080 -0,02 -0,09%
Aegon 6,082 0,00 -0,03%
vlag naam koers verschil relatief verschil
AEX 896,14 +2,72 +0,30%
AEX GR 3.514,96 +10,69 +0,31%
Germany40^ 20.417,60 +88,44 +0,44%
FTSE 100 8.301,62 +21,26 +0,26%
EURO50 4.968,97 +26,71 +0,54%
US30^ 44.239,50 -33,00 -0,07%
Nasd100^ 21.770,50 +390,00 +1,82%
US500^ 6.087,46 +48,09 +0,80%
Japan225^ 40.092,00 +757,70 +1,93%
VD-NEW 12,88 -0,61 -4,53%
#/^ Index indications calculated real time, zie disclaimer